DPP-4 inhibition and neuroprotection: Do mechanisms matter?

Diabetes

Volumn 62, Issue 4, 2013, Pages 1029-1031

  Shannon, Richard P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; LINAGLIPTIN;

ANTIINFLAMMATORY ACTIVITY; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CELL DIFFERENTIATION; CELL INFILTRATION; CELL PROLIFERATION; CELL PROTECTION; DOSE RESPONSE; ENZYME INHIBITION; GLYCEMIC CONTROL; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; INSULIN LIKE ACTIVITY; LIPID DIET; NERVE CELL DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN TARGETING; RENAL PROTECTION; T LYMPHOCYTE ACTIVATION; VASOCONSTRICTION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; PURINES; QUINAZOLINES; STROKE; SULFONYLUREA COMPOUNDS;

EID: 84875439056     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-1794     Document Type: Note

References (14)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary artery disease in type 2 diabetics and non diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
3. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559
4. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572
5. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
6. Holst JJ, Burcelin R, Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 2011;27:547-558
7. Salcedo I, Tweedie D, Li Y, Greig NH. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol 2012;166: 1586-1599
8. Darsalia V, Ortsäter H, Olverling A, et al. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes 2013;62:1289-1296
9. Darsalia V, Mansouri S, Ortsäter H, et al. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin Sci (Lond) 2012;122:473-483
10. Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation 2008;5:19
11. Lee CH, Yan B, Yoo KY, et al. Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia. J Neurosci Res 2011;89:1103-1113
12. Teramoto S, Miyamoto N, Yatomi K, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab 2011;31:1696-1705
13. Li Y, Perry T, Kindy MS, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 2009;106: 1285-1290
14. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012;33:187-215